Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002

Digestive and Liver Disease

Volumn 35, Issue 8, 2003, Pages 541-545

  Toracchio, S ^a   Marzio, L ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antibiotic resistance; Helicobacter pylori; Susceptibility testing

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; TINIDAZOLE; ANTIINFECTIVE AGENT; ANTITRICHOMONAL AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; FEMALE; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STOMACH BIOPSY; TREATMENT FAILURE; UREA BREATH TEST; ADOLESCENT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; URBAN POPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTITRICHOMONAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SEX FACTORS; TINIDAZOLE; URBAN POPULATION;

EID: 2142774070     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00265-2     Document Type: Article

References (27)

1. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720-41.
2. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41:8-13.
3. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998;115:1272-7.
4. Mégraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998;115:1278-82.
5. Bazzoli F, Olivieri L, De Luca L, Pozzato P, Lehours P, Mégraud F. Therapy and drug resistance in Helicobacter pylori infection. Dig Liver Dis 2000;32(Suppl 3):S207-10.
6. Mégraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998;54:207-16.
7. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999;43:511-5.
8. Dore MP, Sepulveda AR, Mura I, Realdi G, Osato MS, Graham DY. Explanation for variability of omeprazole amoxycillin therapy? Tolerance of H. pylori to amoxycillin. Gastroenterology 1997;112:A105.
9. Fedorak R, Archambault A, Flamm R, Osato M, Stamler D. Antimicrobial susceptibility of H. pylori in Canada to three key antibiotics: metronidazole, clarithromycin, and amoxicillin. Gastroenterology 1997;112:A115.
10. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
11. Pilotto A, Franceschi M, Rassu M, Leandro G, Bozzola L, Furlan F, et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000;32:667-72.
12. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001;15:707-13.
13. Samra Z, Shmuely H, Niv Y, Dinari G, Passaro DJ, Geler A, et al. Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother 2002;49:1023-6.
14. Tucci A, Varoli O, Corinaldesi R, Stanghellini V, Gasperoni S, Paparo GF, et al. Evaluation of Helicobacter pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients. Ital J Gastroenterol 1993;25:65-7.
15. Landi F, Acciardi C, Figura N, Ricci C, Menegatti M, Alì A, et al. Clinical relevance of Helicobacter pylori susceptibility strains before and after unsuccessful treatment. Gut 1999;45(Suppl 3):A109.
16. Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. Dig Liver Dis 2000;32:763-8.
17. Mégraud F, Bonnet F, Garnier M, Lamouliatte H. Characterization of 'Campylobacter pyloridis' by culture, enzymatic profile, and protein content. J Clin Microbiol 1985;22:1007-10.
18. Boyanova L, Spassova Z, Krastev Z, Petrov S, Stancheva I, Docheva J, et al. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over 4 years. Diagn Microbiol Infect Dis 1999;34:309-13.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing-Fourth Information Supplement; Document M100-S4. NCCLS, Villanova, P.A., 1992.
20. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Fifth Edition M7-A5. NCCLS, Villanova, P.A., 2001.
21. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000;46:1029-31.
22. Wolle K, Nilius M, Leodolter A, Muller WA, Malfertheiner P, Koning W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis 1998;17:519-21.
23. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
24. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. New Engl J Med 2001;345:784-9.
25. Des Varannes SB, Fléjou JF, Colin R, Zaim M, Meunier A, Bidaut-Mazel C. There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001;15:1177-85.
26. Moayyedi P, Zilles A, Clough M, Hemingbrough E, Chalmers DM, Axon AT. The effectiveness of screening and treating Helicobacter pylori in the management of dyspepsia. Eur J Gastroenterol Hepatol 1999;11:1245-50.
27. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.